Cardioplegia and Angiotensin II Receptor Antagonists Modulate Signal Transducers and Activators of Transcription Activation in Neonatal Rat Myocytes

Artificial Organs

Volumn 35, Issue 11, 2011, Pages 1075-1081

  Lucchese, Gianluca ^a   Cambi, Giulia Elisa ^b   De Rita, Fabrizio ^a   Faggian, Giuseppe ^a   Mazzucco, Alessandro ^a   Modesti, Pietro Amedeo ^b   Luciani, Giovanni Battista ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Angiotensin II antagonist; Cardioplegia; Rat myocardium; Signal transducers and activators of transcription; Valsartan

Indexed keywords

AMINO ACIDS; CELL DEATH; CHEMICAL ACTIVATION; PHOSPHORYLATION; TRANSCRIPTION; TRANSDUCERS;

% REDUCTIONS; ANGIOTENSIN II; ANGIOTENSIN II ANTAGONIST; ANTIAPOPTOTIC; CARDIOPLEGIA; ISCHAEMIA; RAT MYOCARDIUM; RECEPTOR ANTAGONISTS; SIGNAL TRANSDUCERS AND ACTIVATORS OF TRANSCRIPTIONS; VALSARTAN;

RATS;

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CARDIOPLEGIC AGENT; INTERLEUKIN 1BETA; STAT PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; VALSARTAN;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOPLEGIA; CELL ISOLATION; ENZYME DEGRADATION; HEART MUSCLE CELL; HEART PROTECTION; INFLAMMATION; ISOLATED HEART; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; WESTERN BLOTTING;

EID: 81855185475     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2011.01386.x     Document Type: Article

References (31)

1. Bull C, Cooper J. Cardioplegic protection of the child's heart. J Thorac Cardiovasc Surg 1984;88:287-93.
2. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002;3:651-62.
3. Allen BS. Pediatric myocardial protection: where do we stand? J Thorac Cardiovasc Surg 2004;128:11-3.
4. Ruel M, Khan TA, Voisine P, Bianchi C, Sellke FW. Vasomotor dysfunction after cardiac surgery. Eur J Cardiothorac Surg 2004;26:1002-14.
5. Ellis RJ, Mavroudis C, Gardner C, Turley K, Ullyot D, Ebert PA. Relationship between atrioventricular arrhythmias and the concentration of K+ ion in cardioplegic solution. J Thorac Cardiovasc Surg 1980;80:517-26.
6. Spinale FG. Cellular and molecular therapeutics targets for treatment of contractile dysfunction after cardioplegic arrest. Ann Thorac Surg 1999;68:1934-41.
7. Chambers DJ, Hearse DJ. Cardioplegia and surgical ischaemia. In: Sperelakis N, Kurachi Y, Terzic A, Cohen MV, eds. Heart Physiology and Pathophysiology. San Diego: Academic Press, 2001;887-926.
8. Prondzinsky R, Knupfer A, Loppnow H, etal. Surgical trauma affects the proinflammatory status after cardiac surgery to a higher degree than cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005;129:760-6.
9. Mackay K, Mochly-Rosen D. Involvement of a p38 mitogen-activated protein kinase phosphatase in protecting neonatal rat cardiac myocytes from ischemia. J Mol Cell Cardiol 2000;32:1585-8.
10. Neri Serneri GG, Boddi M, Cecioni I, etal. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res 2001;88:961-8.
11. Cook SA, Sugden PH, Clerk A. Activation of c-Jun N-terminal kinases and p38 mitogen-activated protein kinases in human heart failure secondary to ischemic heart disease. J Mol Cell Cardiol 1999;31:1429-34.
12. Communal C, Colucci WS, Remondino A, Sawyer DB, Port JD, Wichman SE. Reciprocal modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatase 1 and 2 in failing human myocardium. J Card Fail 2002;8:86-92.
13. Modesti A, Bertolozzi I, Gamberi T, etal. Hyperglycemia activates JAK2 signaling pathway in human failing myocytes via angiotensin II-mediated oxidative stress. Diabetes 2005;54:394-401.
14. Ledingham SJM, Braimbridge MV, Hearse DJ. The St. Thomas' Hospital cardioplegic solution: a comparison of the efficacy of two formulations. J Thorac Cardiovasc Surg 1987;93:240-6.
15. Robinson LA, Braimbridge MV, Hearse DJ. Comparison of the protective properties of four clinical crystalloid cardioplegic solutions in the rat heart. Ann Thorac Surg 1984;38:268-74.
16. Konishi T, Apstein CS. Comparison of three cardioplegic solutions during hypothermic ischemic arrest in neonatal blood-perfused rabbit hearts. J Thorac Cardiovasc Surg 1989;98:1132-7.
17. Yamamoto F, Braimbridge MV, Hearse DJ. Calcium and cardioplegia. The optimal calcium content for the St. Thomas' hospital cardioplegic solution. J Thorac Cardiovasc Surg 1984;87:908-12.
18. Douglas JG. Potassium ion as a regulator of adrenal angiotensin II receptors. Am J Physiol 1980;239:E317-21.
19. McCully JD, Wakiyama H, Hsieh Y-J, Jones M, Levitsky S. Differential contribution of necrosis and apoptosis in myocardial ischemia/reperfusion injury. Am J Physiol Heart Circ Physiol 2004;286:H1923-35.
20. Zhong Z, Wen Z, Darnell JE Jr. STAT3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994;264:95-8.
21. Meraz MA, White JM, Sheehan KCF, etal. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996;84:431-42.
22. Stephanou A. Activated STAT-1 pathway in the myocardium as a novel therapeutic target in ischaemia/reperfusion injury. Eur Cytokine Netw 2002;13:401-3.
23. Smith RM, Suleman N, Lacerda L, etal. Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning. Cardiovasc Res 2004;63:611-6.
24. Ardaillou R. Angiotensin II receptors. J Am Soc Nephrol 1999;10(Suppl. 11):S30-9.
25. McCully JD, Wakiyama H, Cowan DB, Federman M, Levitsky S. Diazoxide amelioration of myocardial injury and mitochondrial damage during cardiac surgery. Ann Thorac Surg 2002;74:2138-46.
26. Yoo YJ, Wang W, Desiderio S, Nathans D. Synergistic activity of STAT3 and c-Jun at a specific array of DNA elements in the alpha 2-macroglobulin promoter. J Biol Chem 2001;276:26421-9.
27. Mann DL. Stress activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol 2003;65:81-101.
28. Hogquist KA, Nett MA, Unanue ER, Chaplin DD. Interleukin 1 is processed and released during apoptosis. Proc Natl Acad Sci U S A 1991;88:8485-9.
29. Van Tassell BW, Varma A, Salloum FN, etal. Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice. J Cardiovasc Pharmacol 2010;55:117-22.
30. Hennein HA, Ebba H, Rodriguez JL, etal. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 1994;108:626-35.
31. Valen G. The biology of apoptosis and its implications for cardiac function and viability. Ann Thorac Surg 2003;75(Suppl.):656-60.